Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.152
Sell
RSI(14)
43.022
Neutral
STOCH(KDJ)(9,3,3)
22.462
Neutral
ATR(14)
1.415
High Vlolatility
CCI(14)
-105.253
Sell
Williams %R
71.175
Sell
TRIX(12,20)
-0.365
Sell
StochRSI(14)
62.573
Buy
Neurogene Inc
NGNE17.230USD
+0.860+5.25%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
254.58MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Neurogene Inc
Currency: USD Updated: 2026-02-06Key Insights
Neurogene Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 73 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 59.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Neurogene Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Neurogene Inc Highlights
StrengthsRisks
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 925.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 925.00K.
Fairly Valued
The company’s latest PE is -4.20, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 16.38M shares, decreasing 12.93% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 845.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.48.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
59.000
Target Price
+243.42%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Neurogene Inc is 5.49, ranking 358 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Score
Financials
3.51
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.44
Operational Efficiency
2.69
Growth Potential
6.78
Shareholder Returns
7.03
Neurogene Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Neurogene Inc is 7.41, ranking 124 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.20, which is -1406.96% below the recent high of 54.85 and -328.29% above the recent low of -17.97.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 73/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Neurogene Inc is 9.00, ranking 15 out of 392 in the Biotechnology & Medical Research industry. The average price target is 60.00, with a high of 70.00 and a low of 46.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
59.000
Target Price
+243.42%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Neurogene Inc
NGNE
6
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Neurogene Inc is 7.07, ranking 110 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 19.80 and the support level at 15.29, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
17.334
Sell
MA10
18.148
Sell
MA20
18.058
Sell
MA50
19.317
Sell
MA100
22.413
Sell
MA200
20.770
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Neurogene Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 105.73%, representing a quarter-over-quarter decrease of 3.93%. The largest institutional shareholder is The Vanguard, holding a total of 656.57K shares, representing 4.24% of shares outstanding, with 2.17% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Neurogene Inc is 2.86, ranking 192 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.61. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.60
VaR
+7.92%
240-Day Maximum Drawdown
+58.72%
240-Day Volatility
+105.38%
Return
Best Daily Return
60 days
+10.91%
120 days
+22.18%
5 years
+43.26%
Worst Daily Return
60 days
-14.77%
120 days
-14.77%
5 years
-44.08%
Sharpe Ratio
60 days
-1.93
120 days
+0.05
5 years
-0.13
Risk Assessment
Maximum Drawdown
240 days
+58.72%
3 years
+89.74%
5 years
+97.17%
Return-to-Drawdown Ratio
240 days
+0.06
3 years
+0.13
5 years
-0.19
Skewness
240 days
+0.94
3 years
+0.13
5 years
+0.43
Volatility
Realised Volatility
240 days
+105.38%
5 years
+100.05%
Standardised True Range
240 days
+10.63%
5 years
+18.82%
Downside Risk-Adjusted Return
120 days
+8.54%
240 days
+8.54%
Maximum Daily Upside Volatility
60 days
+51.13%
Maximum Daily Downside Volatility
60 days
+51.85%
Liquidity
Average Turnover Rate
60 days
+1.10%
120 days
+1.46%
5 years
--
Turnover Deviation
20 days
-48.35%
60 days
-23.66%
120 days
+1.45%
Peer Comparison
Biotechnology & Medical Research
Neurogene Inc
NGNE
6.98 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
